{"id":9351,"date":"2024-02-13T17:18:54","date_gmt":"2024-02-13T17:18:54","guid":{"rendered":"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=9351"},"modified":"2024-02-13T17:18:54","modified_gmt":"2024-02-13T17:18:54","slug":"mabmods-chimeric-anti-mouse-antibodies","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/mabmods-chimeric-anti-mouse-antibodies\/","title":{"rendered":"mAbMods&#x2122; Chimeric Anti-Mouse Antibodies"},"content":{"rendered":"\n<figure class=\"wp-block-image alignleft size-large is-resized\"><a href=\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-117.png\"><img loading=\"lazy\" decoding=\"async\" width=\"957\" height=\"1024\" src=\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-117-957x1024.png\" alt=\"\" class=\"wp-image-9352\" style=\"width:252px;height:auto\" srcset=\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-117-957x1024.png 957w, https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-117-280x300.png 280w, https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-117-768x822.png 768w, https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-117.png 1200w\" sizes=\"auto, (max-width: 957px) 100vw, 957px\" \/><\/a><\/figure>\n\n\n\n<p>Recombinant\u00a0chimeric\u00a0antibodies offer many advantages over those produced from traditional hybridoma technology. These include reduced immunogenicity, the ability to mute effector functions to avoid unwanted side effects, and decreased potential for genetic drift. The combination of these factors makes recombinant antibodies an excellent choice for pre-clinical\u00a0<em>in vivo<\/em>\u00a0functional studies where prolonged and repeated administration of these antibodies is necessary.<\/p>\n\n\n\n<p>mAbMods&#x2122; recombinant antibodies have been engineered to have identical antigen binding variable domains to those of the traditional clones from which they are derived, but the IgG constant regions have been engineered to be of mouse origin. This reduces immunogenic responses in the mouse, which can lead to adverse immunological reactions and gradual loss of activity.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-118.png\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"234\" src=\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-118-1024x234.png\" alt=\"\" class=\"wp-image-9357\" style=\"width:1024px;height:auto\" srcset=\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-118-1024x234.png 1024w, https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-118-300x69.png 300w, https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-118-768x176.png 768w, https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-118-1536x351.png 1536w, https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-118-2048x468.png 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p class=\"clear\">Fc Muted mAbMods&#x2122; recombinant\u00a0chimeric\u00a0antibodies have engineered mutations (LALA-PG or D265A) in the Fc domain that reduce or eliminate the Fc\u03b3R binding. This reduces Fc-mediated effector functions such as Antibody-Dependent Cellular Cytotoxicity (ADCC), Antibody-Dependent Cellular Phagocytosis (ADCP), and Complement-Dependent Cytotoxicity that can lead to unwanted side effects.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-119.png\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"449\" src=\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-119-1024x449.png\" alt=\"\" class=\"wp-image-9360\" style=\"width:454px;height:auto\" srcset=\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-119-1024x449.png 1024w, https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-119-300x132.png 300w, https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-119-768x337.png 768w, https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-119-1536x674.png 1536w, https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-119-2048x898.png 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background clear\" style=\"background-color:#21318f;color:#21318f\"\/>\n\n\n\n<p>Originally posted by Leinco Technologies Inc. on: <a href=\"https:\/\/www.leinco.com\/chimeric-antibodies\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.leinco.com\/chimeric-antibodies\/<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.caltagmedsystems.co.uk\/\">Caltag Medsystems&nbsp;<\/a>is the distributor of Leinco Technologies\u2019 products in the UK and Ireland. If you have any questions about these products, please&nbsp;<a href=\"https:\/\/www.caltagmedsystems.co.uk\/contact.php\">contact us<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Leinco Technologies offers recombinant chimeric antibodies which offer many advantages over those produced from traditional hybridoma technology.<\/p>\n","protected":false},"author":13,"featured_media":8987,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[132,1],"tags":[185,775,734,776,584],"class_list":["post-9351","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-antibodies","category-general-information","tag-antibodies","tag-chimeric","tag-leinco-technologies","tag-mabmods","tag-recombinant-antibodies"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/9351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=9351"}],"version-history":[{"count":12,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/9351\/revisions"}],"predecessor-version":[{"id":9366,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/9351\/revisions\/9366"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/8987"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=9351"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=9351"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=9351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}